Skip to main content
SpringerLink
Log in

ISIS 5320

NSC 665353

  • Section 2: HIV Fusion Inhibitor
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Buckeit, Jr RW, Roberson JR, Wyatt JR, et al. Biological and biochemical anti-HIV activity of a phosphorothioate G-quartet (TTGGGGTT). Antiviral Res 1994; 23 Suppl. 1: 55

    Google Scholar 

  2. Stoddart CA, Rabin L, Hincenbergs M, et al. Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Livmice by the G-quartet-forming oligonucleotide, ISIS 5320. Antimicrob Agents Chemother 1998 Aug; 42: 2113–5

    PubMed  CAS  Google Scholar 

  3. Wyatt JR, Vickers TA, Roberson JL, et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A 1994 Feb 15; 91: 1356–60

    Article  PubMed  CAS  Google Scholar 

  4. Buckheit, Jr RW, Roberson JL, Lackman-Smith C, et al. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding byG quartet-forming oligonucleotide (ISIS 5320). AIDS Res Hum Retroviruses 1994 Nov; 10: 1497–506

    Article  PubMed  CAS  Google Scholar 

  5. Isis Pharmaceuticals. Isis begins phase I clinical trials of anti- HIV compound [press release]. PR Newswire. 1997 Jan 29

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

ISIS 5320. Drugs R&D 2, 345–346 (1999). https://doi.org/10.2165/00126839-199902050-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902050-00015

Keywords

Search

Navigation